Phase 3
Completed N=371
Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis
Scalp Psoriasis
Source: ClinicalTrials.gov NCT02933866 ↗
Enrolled (actual)
371
Serious AEs
0.0%
Results posted
Dec 2018
Primary outcomePrimary: Proportion of Patients in Each Treatment Group Who Are Considered a Clinical Success — 49; 41 Participants — p=0.2961
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site, Phase III Clinical Study to Evaluate the Efficacy and Safety of DSXS topical product in Patients with Mild to Severe Scalp Psoriasis
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Proportion of Patients in Each Treatment Group Who Are Considered a Clinical Success |
49; 41 | 0.2961 |
Eligibility Criteria
Inclusion Criteria
- Male or non-pregnant, non-lactating females 18 years of age and older.
Exclusion Criteria
- Females who are pregnant, lactating or likely to become pregnant during the study.
Data sourced from ClinicalTrials.gov (NCT02933866). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.